Targets › DCTD
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Dec 2026.
Catalyzes the deamination of dCMP to dUMP, providing the nucleoside monophosphate substrate for the thymidylate synthase/TYMS. Also, part of a nucleotide salvage pathway that eliminates epigenetically modified 5-hydroxymethyl-dCMP (hmdCMP) in a two-step process entailing deamination to cytotoxic 5-hydroxymethyl-dUMP (hmdUMP), followed by its hydrolysis into 5-hydroxymethyluracil (hmU) and 2-deoxy-D-ribose…. (UniProt, P32321)
Open in Phaseline: the race on DCTD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhongnan Hospital | Ara-Cytarabine Cytidine analog; DNA synthesis inhibitor | DCTD | Phase 3 | Acute Myeloid Leukaemia | Dec 2026 |
Acute Myeloid Leukaemia (1)
small molecule (1)
Zhongnan Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.